acromegaly
Endocrinology · 2015–2024
6decisions
4medicines
3carried consumer input
6individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lanreotide Changes to Community Access (CA) listings to allow initiation of treatment for acromegaly, functional carcinoid tumour, and non-functional… | Jul 2024 | Recommended with restriction | 3 individuals |
| lanreotide Treatment of acromegaly, functional carcinoid tumour, and gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adult patients with unresectable locally… | Nov 2022 | Recommended with restriction | input received NeuroEndocrine Cancer Australia |
| pegvisomant Second-line treatment for acromegaly in patients who have failed to achieve biochemical control with maximum indicated doses of somatostatin analogues… | Mar 2019 | Recommended | none received |
| octreotide Extension of listing for octreotide modified release injection for treatment of acromegaly and symptomatic treatment of carcinoid tumours and vasoactive… | Jul 2018 | Recommended with restriction | none received |
| pegvisomant Treatment of active acromegaly in patients who have failed to achieve biochemical control with somatostatin analogues (SSAs). | Nov 2016 | Recommended with restriction | 3 individuals |
| pasireotide Treatment of acromegaly in patients inadequately controlled with either octreotide LAR 30mg or lanreotide autogel 120mg. | Nov 2015 | Recommended with restriction | none received |
Who spoke
NeuroEndocrine Cancer Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 6 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.